I-Mab SEC Filings

NovaBridge Biosciences filed a Rule 424(b)(3) prospectus for its American Depositary Shares under a Form F-6 program. The ADR outlines how holders own ADSs representing deposited ordinary shares of the Cayman Islands company (formerly I‑Mab). As of issuance, each ten (10) ADSs represent the right to receive twenty‑three (23) ordinary shares, a ratio that is subject to amendment under the Deposit Agreement. Citibank, N.A. is the depositary and Citibank, N.A. – Hong Kong is the custodian; the ADSs are eligible for DTC.

The filing details key mechanics: surrender and withdrawal of deposited securities, transfers, split‑ups, record dates, cash and share distributions, elective distributions, and rights offerings. Voting occurs via depositary instructions, with procedures for show‑of‑hands and poll voting. The company may impose ownership and transfer restrictions consistent with its Articles and applicable law. ADS fee schedules apply, and taxes or charges may be withheld from distributions.

The document also covers changes affecting deposited securities, redemption processes, amendment and termination of the program, New York governing law, and a waiver of jury trial. A legend addresses potential “partial entitlement” ADSs.

NovaBridge Biosciences (formerly I-MAB) announced a corporate name change and Nasdaq ticker update. The company filed a certificate in the Cayman Islands on October 27, 2025, reflecting the new name.

Its American Depositary Shares will begin trading on the Nasdaq Global Market under the new ticker NBP at the open on October 30, 2025. The company stated that no action is required by shareholders in connection with the name and ticker change.

I-Mab (IMAB) closed its acquisition of Bridge Health Biotech, completing a previously disclosed deal through wholly owned subsidiary I-Mab Biopharma Hong Kong Limited. Under the agreement, Bridge Health shareholders receive an upfront $1.8 million and additional non-contingent payments of $1.2 million through 2027, plus up to $3.875 million in milestone payments tied to development and regulatory achievements.

The acquisition provides rights to bispecific and multi-specific applications based on the Claudin 18.2 (CLDN18.2) parental antibody, including bispecifics and ADCs, complementing I-Mab’s CLDN18.2 x 4-1BB bispecific antibody, givastomig. This is a cash-out transaction tied to defined milestones.

I-Mab reported results of its extraordinary general meeting. Shareholders approved changing the Company’s English name to NovaBridge Biosciences, effective as of the date of the certificate of incorporation on change of name issued by the Registrar of Companies in the Cayman Islands. They also approved the seventh amended and restated memorandum and articles of association, effective as of the date of the name change.

Quorum was met with 90,174,250 shares present in person or by proxy, representing approximately 34% of the 265,111,923 shares outstanding as of the September 12, 2025 record date. The name change resolution received 90,149,771 for, 23,025 against, and 1,454 abstain. The amended charter resolution received 90,142,346 for, 26,583 against, and 5,321 abstain.

I-Mab filed an amended Form 6-K to add Exhibits 1.1–1.4 to its prior report. The added exhibits cover a Series A Preferred Stock Subscription Agreement (Visara, Inc., I-Mab, and AffaMed Therapeutics (HK) Limited, dated October 14, 2025), an Assignment and Assumption Agreement (Visara and AffaMed, dated October 14, 2025), and two Exclusive License Agreements (AskGene Pharma with AffaMed, dated November 6, 2021; and AskGene Pharma with Visara, dated October 15, 2025). The amendment states these exhibits are incorporated by reference into I-Mab’s Form F-3 (File No. 333-286954) and multiple Form S-8s. Except as noted, no other changes were made.

I-Mab furnished a Form 6-K announcing an investor presentation as Exhibit 99.1. The exhibit provides updated safety, efficacy, and biomarker analysis from a Phase I monotherapy study of Givastomig, a Claudin 18.2/4-1BB bispecific antibody, in Claudin 18.2 positive advanced gastroesophageal carcinoma.

The company states that Exhibit 99.1 is incorporated by reference into its Registration Statements on Form F-3 and Form S-8, making the presentation part of those filings from the furnishing date, to the extent not superseded. This is an informational update; no transaction terms or financial results are disclosed in the document provided.

I-Mab furnished a Form 6-K announcing it will present positive updated data for its Givastomig monotherapy at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025.

Exhibit 99.1, a press release with these details, is incorporated by reference into the company’s existing registration statements on Forms F-3 and S-8.